Rapamycin (Sirolimus): A two-edged sword?

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 2, 2006, Pages 226-227

  J Gross, Garrett ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

APOPTOSIS; CARDIAC GRAFT REJECTION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CORRELATION ANALYSIS; EDITORIAL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REOXYGENATION; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

ANIMALS; APOPTOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED ICR; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; VENTRICULAR FUNCTION;

EID: 33746069344     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.04.013     Document Type: Editorial

References (14)

1. Kahan B.D., and For the rapamune US study group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter trial. Lancet 356 (2000) 194-202
2. Keogh A., Richardson M., Ruygrok P., Spratt P., Galbraith A., Driscoll O., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
3. Hausleiter J., Kastrati A., Mehilli J., Vogeser M., Zohlnhofer D., Schuhlen H., et al. Randomized, double-blind placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial. Circulation 110 (2004) 790-795
4. Marx S.O., Jayaraman T., Go L.O., and Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
5. Asnaghi L., Bruno P., Priulla M., and Nicolin A. mTOR: a protein kinase switching between life and death. Pharmacol Res 50 (2004) 545-549
6. Kozma S.C., and Thomas G. Regulation of cell size in growth, development and human disease: P13K, PKB and S6K. BioEssays 24 (2002) 65-71
7. Hausenloy D.J., Tsang A., Mocanu M.M., and Yellon D.M. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol 288 (2005) H971-H976
8. Jonassen A.K., Sack M.N., Mjos O.D., and Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89 (2001) 1191-1198
9. Kis A., Yellon D.M., and Baxter G.F. Second window of protection following myocardial preconditioning: an essential role for PI3K kinase and p70S6 kinase. J Mol Cell Cardiol 35 (2003) 1063-1071
10. Khan S, Salloum F, Das A, Xi L, Vetrovec GW, Kukreja RA. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol. doi:10.1016/j.yjmcc.2006.04.014.
11. Jenkins D.P., Pugsley W.B., and Yellon D.M. Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction in stunning. J Mol Cell Cardiol 27 (1995) 1623-1632
12. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., et al. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113 (2004) 1535-1549
13. Gross E.R., Hsu A.K., and Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circ Res 94 (2004) 960-966
14. Critz S.D., Cohen M.V., and Downey J.M. Mechanisms of acetylcholine and bradykinin-induced preconditioning. Vascul Pharmacol 42 (2005) 201-209